Business Context and Reporting Period
Company: PharmaCyte Biotech, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 15, 2016
Event: Entry into a Material Definitive Agreement (Amendment to Engagement Agreement).
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on a contractual amendment regarding securities sales.
Material Changes
The Company entered into an amendment (the "Chardan Amendment") with Chardan Capital Markets, LLC on December 15, 2016, modifying a previously disclosed engagement agreement. Key changes include:
- Extension of Engagement: Chardan is authorized to act as a sales agent for the sale of up to $50,000,000 of the Company's common stock via "at the market" or privately negotiated transactions, subject to market conditions and Company discretion.
- Termination Rights: Either party may terminate the agreement for any reason, with or without cause, upon five days' written notice.
- Post-Termination Fees: Chardan retains the right to collect transaction fees on securities sold to parties introduced by Chardan within nine months following the expiration or termination of the agreement.
Guidance, Outlook, and Risks
Outlook: The filing indicates an intent to pursue capital raising through the sale of up to $50 million in common stock, contingent on market conditions.
Risks/Contingencies: The agreement allows for immediate termination with short notice (five days), creating uncertainty regarding the duration of the sales program. The full text of the amendment is incorporated by reference as Exhibit 10.1.
Investor Verification Checklist
- Review Exhibit 10.1 for the complete terms of the Chardan Amendment.
- Verify the Company's current cash position and immediate capital needs to understand the urgency of the $50 million offering.
- Check recent trading volume and price of the Company's common stock to assess the feasibility of the "at the market" sales program.
- Confirm if any shares have been sold under this agreement since December 15, 2016, in subsequent filings.